|
|
|
15.04.26 - 22:18
|
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026 (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its first-quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com.
To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance at http://ir.iqvia.com. Following registration for the call, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a uniq...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.02.26 - 12:24
|
IQVIA to acquire Charles River drug discovery assets (PBR)
|
|
|
The acquisition includes five sites specialising in various in vitro drug discovery services such as New Approach Methodologies (NAMs) and a small molecule AI platform. These assets are
The post IQVIA to acquire Charles River drug discovery assets appeared first on Pharmaceutical Business review....
|
|
|
25.02.26 - 13:06
|
IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories.
These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies (NAMs) and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non animal research methods. Collectively, these assets are underpinned by more than 20 years of curated scientific and operational data, as well as extensive therapeutic expertise. Since their inception, these assets have enabled over 100 molecules to enter clinical trials and include several commercially approved drugs.
The acquisition complements IQVIA Laboratories' existing drug discove...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.02.26 - 14:12
|
IQVIA Q4 Earnings Up; Guides FY26 (AFX)
|
|
|
WASHINGTON (dpa-AFX) - IQVIA Holdings Inc. (IQV), a healthcare data and analytics company, on Thursday reported higher net income and revenue in the fourth quarter compared with the previous year ......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
